Phosphagenics appoints pharma veteran
By Dylan Bushell-Embling
Tuesday, 08 July, 2008
Tuesday, 08 July, 2008
Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.
Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.
Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.
Ashton also served as CEO for SkyePharma PLC.
Related News
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
